205 related articles for article (PubMed ID: 22737276)
1. Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening.
Meng W; Zhu HH; Xu ZF; Cai SR; Dong Q; Pan QR; Zheng S; Zhang SZ
World J Gastrointest Oncol; 2012 Jun; 4(6):145-51. PubMed ID: 22737276
[TBL] [Abstract][Full Text] [Related]
2. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
[TBL] [Abstract][Full Text] [Related]
3. Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps.
Rigi F; Jannatabad A; Izanloo A; Roshanravan R; Hashemian HR; Kerachian MA
BMC Gastroenterol; 2020 Jul; 20(1):241. PubMed ID: 32727566
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study.
Haug U; Hundt S; Brenner H
Br J Cancer; 2008 Jul; 99(1):133-5. PubMed ID: 18542075
[TBL] [Abstract][Full Text] [Related]
5. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
[TBL] [Abstract][Full Text] [Related]
6. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients.
Fatela-Cantillo D; Fernandez-Suarez A; Moreno MA; Gutierrez JJ; Iglesias JM
Tumour Biol; 2012 Jun; 33(3):825-32. PubMed ID: 22231432
[TBL] [Abstract][Full Text] [Related]
8. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.
Tonus C; Sellinger M; Koss K; Neupert G
World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
10. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
[TBL] [Abstract][Full Text] [Related]
11. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT.
Zaccaro C; Saracino IM; Fiorini G; Figura N; Holton J; Castelli V; Pesci V; Gatta L; Vaira D
Intern Emerg Med; 2017 Apr; 12(3):333-339. PubMed ID: 28155016
[TBL] [Abstract][Full Text] [Related]
12. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
[TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
14. Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer.
Wang J; Wang X; Lin S; Chen C; Wang C; Ma Q; Jiang B
PLoS One; 2013; 8(7):e70519. PubMed ID: 23894665
[TBL] [Abstract][Full Text] [Related]
15. Circulating midkine in malignant and non-malignant colorectal diseases.
Krzystek-Korpacka M; Diakowska D; Neubauer K; Gamian A
Cytokine; 2013 Oct; 64(1):158-64. PubMed ID: 23899719
[TBL] [Abstract][Full Text] [Related]
16. Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer.
Song YF; Xu ZB; Zhu XJ; Tao X; Liu JL; Gao FL; Wu CL; Song B; Lin Q
Clin Transl Oncol; 2017 Apr; 19(4):519-524. PubMed ID: 27743169
[TBL] [Abstract][Full Text] [Related]
17. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
18. Fecal CEA Has an Advantage in the Diagnosis of Colorectal Cancer at Early Stage.
Li L; Xing S; Wu M; Ao Y; Zheng X; Cai R; Han R; Li J; Li X; Zeng Q
Cancer Control; 2021; 28():10732748211048292. PubMed ID: 34615391
[TBL] [Abstract][Full Text] [Related]
19. Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas.
De Chiara L; Rodríguez-Piñeiro AM; Rodríguez-Berrocal FJ; Cordero OJ; Martínez-Ares D; Páez de la Cadena M
BMC Cancer; 2010 Jun; 10():333. PubMed ID: 20584285
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of matrix metalloproteinases 2, 7 and 9 in urine for early detection of colorectal cancer.
Peng L; Zhang X; Zhang ML; Jiang T; Zhang PJ
World J Gastrointest Surg; 2023 May; 15(5):931-939. PubMed ID: 37342853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
